Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Clinical trial NCT05310383 · UNKNOWN

Trial details

NCT number: NCT05310383
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Cervical Carcinoma Metastatic Cervical Carcinoma Persistent Cervical Carcinoma Radiotherapy Immunotherapy Anti-programmed Cell Death Receptor 1 Immune Checkpoint Inhibitors Tislelizumab Objective Response Rate Survival Outcomes

Start date: 2022-03-27
Primary completion: 2023-03-27
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.